A revolutionary blood test has been developed to detect minute traces of a deadly form of cancer. This highly sensitive test can identify hidden signs of pancreatic cancer by targeting a crucial genetic mutation that traditional tests often miss.
Researchers in the United States have highlighted the potential of this test in extending the lives of patients by helping doctors identify those at higher risk of cancer recurrence, even when imaging scans show positive results. The test focuses on detecting the KRAS genetic mutation, known to be responsible for more than 90% of pancreatic cancer cases.
A team of scientists from Northwestern University Feinberg School of Medicine in Chicago conducted a study where blood samples from patients with localized pancreatic cancer were analyzed using the new test. The results showed that at the time of diagnosis, the sensitive test detected cancer indications in 65% of patients, significantly higher than the 17% detection rate of standard tests.
Following chemotherapy and surgery, the sensitive test continued to identify residual cancer in most patients, even when imaging techniques failed to do so. These findings, published in the journal Clinical Cancer Research, come at a time when a new drug targeting the KRAS mutation is showing promising survival outcomes.
Lead author Professor Akhil Chawla emphasized the importance of having a screening tool that tracks the same mutation targeted by emerging therapies. This advancement could revolutionize the identification of high-risk patients, monitoring of microscopic disease, and early intervention to prevent visible recurrence, potentially increasing the number of patients who achieve a cure.
Pancreatic cancer is known for its high fatality rate, even when detected early. Patients often undergo extensive treatments, yet the cancer frequently returns. Prof Chawla noted the challenge of detecting circulating tumor DNA levels in these patients, highlighting the need for more precise monitoring tools.
The study, which followed 106 patients with localized pancreatic cancer, demonstrated the superior performance of the new blood test, digital droplet PCR (ddPCR), compared to conventional next-generation sequencing tests (NGS). The ddPCR test consistently detected cancer indications in a significantly higher number of patients both before and after treatment, showcasing its potential for improved detection and survival prediction.
The study’s most significant discovery was the identification of a group of high-risk patients who were missed by standard testing but detected by ddPCR. This group had a shorter survival period compared to patients who tested negative on both assessments, underscoring the importance of accurate and early detection in improving outcomes for pancreatic cancer patients.
In conclusion, the study highlights the impact of advanced blood tests, like ddPCR, in providing early indications of cancer presence or recurrence, ultimately offering hope for better monitoring and treatment outcomes for patients.
